Prognostic value of soluble suppression of tumorigenesis-2 (sST2) for cardiovascular events in coronary artery disease patients with and without diabetes mellitus

Table 4 Reclassification and discrimination statistics for clinical outcomes by plasma sST2

Clinical outcomes	Model	C-index		Continuous NRI,%		IDI,%
Clinical outcomes	Model	Estimate (95%CI)	P value	Estimate (95%CI)	P value	Estimate (95%CI)	P value
MACEs	Model1	0.586(0.559–0.603)	< 0.001	REF	< 0.001	REF	< 0.002
MACEs	Model1 + sST2	0.619(0.605–0.638)	< 0.001	17.8 (9.4–26.2)	< 0.001	0.9 (0.3–1.4)	< 0.002
Cardiac death	Model1	0.746(0.703–0.789)	< 0.001	REF	< 0.001	REF	< 0.001
Cardiac death	Model1 + sST2	0.783(0.743–0.823)	< 0.001	27.9 (15.9–34.5)	< 0.001	0.8 (0.2–1.6)	< 0.001
MI	Model1	0.644(0.564–0.715)	0.352	REF	0.561	REF	0.721
MI	Model1 + sST2	0.655(0.582–0.729)	0.352	15.3 (9.7–20.0)	0.561	1.2 (0.8–2.8)	0.721
Unstable angina	Model1	0.583(0.561–0.608)	< 0.001	REF	0.015	REF	0.001
Unstable angina	Model1 + sST2	0.601(0.583–0.617)	< 0.001	18.2 (10.4–31.4)	0.015	0.07 (0.01–0.26)	0.001
Revascularization	Model1	0.575(0.545–0.596)	< 0.001	REF	< 0.001	REF	< 0.001
Revascularization	Model1 + sST2	0.584(0.572–0.609)	< 0.001	16.7 (3.9–22.3)	< 0.001	1.4 (0.6–1.8)	< 0.001
All-cause death	Model1	0.642(0.594–0.701)	< 0.001	REF	< 0.001	REF	< 0.001
All-cause death	Model1 + sST2	0.766(0.717–0.806)	< 0.001	34.2 (11.8–54.7)	< 0.001	1.2 (0.4–1.3)	< 0.001

ISSN: 1475-2840